

INIM0031: Neoplasia and its Treatment

[View Online](#)

-
1.
Weinberg RA. The biology of cancer. 2nd ed. New York: Garland Science; 2014.
 2.
Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell. 2000 Jan;100(1):57–70.
 3.
Lazebnik Y. What are the hallmarks of cancer? Nature Reviews Cancer. 2010 Apr;10(4):232–3.
 4.
Jeggo PA, Pearl LH, Carr AM. DNA repair, genome stability and cancer: a historical perspective. Nature Reviews Cancer. 2015 Dec 15;16(1):35–42.
 5.
Roos WP, Thomas AD, Kaina B. DNA damage and the balance between survival and death in cancer biology. Nature Reviews Cancer. 2015 Dec 18;16(1):20–33.
 6.
Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFN γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001 Apr;410(6832):1107–11.

7.

Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity maintains occult cancer in an equilibrium state. *Nature*. 2007 Dec 6;450(7171):903–7.

8.

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. *New England Journal of Medicine*. 2010 Aug 19;363(8):711–23.

9.

Robert D. Schreiber, Lloyd J. Old and Mark J. Smyth. Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion. *Science* [Internet]. 2011;331(6024):1565–70. Available from: http://www.jstor.org/stable/29783923?seq=1#page_scan_tab_contents

10.

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. *New England Journal of Medicine*. 2012 Jun 28;366(26):2443–54.

11.

Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia. *New England Journal of Medicine*. 2013 Apr 18;368(16):1509–18.

12.

Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1. *Journal of Clinical Oncology*. 2011 Mar;29(7):917–24.

13.

Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. *Science*. 2015 Apr 3;348(6230):69–74.

14.

Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers. *Nature Medicine*. 2016 Jan 6;22(1):26–36.

15.

Morris EC, Stauss HJ. Optimizing T-cell receptor gene therapy for hematologic malignancies. *Blood*. 2016 Jun 30;127(26):3305–11.

16.

de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. *The Lancet Oncology*. 2012 Jun;13(6):607–15.

17.

zur Hausen H. Papillomaviruses in the causation of human cancers — a brief historical account. *Virology*. 2009 Feb;384(2):260–5.

18.

Ajila V, Shetty H, Babu S, Shetty V, Hegde S. Human Papilloma Virus Associated Squamous Cell Carcinoma of the Head and Neck. *Journal of Sexually Transmitted Diseases*. 2015;2015:1–5.

19.

Spurgeon ME, Lambert PF. Merkel cell polyomavirus: A newly discovered human virus with oncogenic potential. *Virology*. 2013 Jan;435(1):118–30.

20.

Wendzicki JA, Moore PS, Chang Y. Large T and small T antigens of Merkel cell

polyomavirus. *Current Opinion in Virology*. 2015 Apr;11:38–43.

21.

Schinzari V, Barnaba V, Piconese S. Chronic hepatitis B virus and hepatitis C virus infections and cancer: synergy between viral and host factors. *Clinical Microbiology and Infection*. 2015 Nov;21(11):969–74.

22.

Lingyun Geng. Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments. *International Journal of Clinical and Experimental Medicine* [Internet]. 2015;8(9). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4658837/>

23.

Weiss RA, Vogt PK. 100 years of Rous sarcoma virus. *The Journal of Experimental Medicine*. 2011 Nov 21;208(12):2351–5.

24.

Matsuoka M, Jeang KT. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. *Oncogene*. 2011 Mar 24;30(12):1379–89.

25.

Pierangeli A, Antonelli G, Gentile G. Immunodeficiency-associated viral oncogenesis. *Clinical Microbiology and Infection*. 2015 Nov;21(11):975–83.

26.

Reichert JM. Antibodies to watch in 2017. *mAbs*. 2017 Feb 17;9(2):167–81.

27.

Reichert JM. Antibodies to watch in 2016. *mAbs*. 2016 Feb 17;8(2):197–204.

28.

Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. *mAbs*. 2015 Jan 2;7(1):9-14.

29.

Reichert JM. Marketed therapeutic antibodies compendium. *mAbs*. 2012 May;4(3):413-5.

30.

Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. *Cancer Gene Therapy*. 2002 Dec;9(12):967-78.

31.

Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. *Nature Biotechnology*. 2012 Jul 10;30(7):658-70.

32.

Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. *Nature Reviews Drug Discovery*. 2015 Sep 1;14(9):642-62.

33.

Larson C, Oronsky B, Scicinski J, Fanger GR, Stirn M, Oronsky A, et al. Going viral: a review of replication-selective oncolytic adenoviruses. *Oncotarget*. 2015 Aug 21;6(24).

34.

Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. *Nature Reviews Immunology*. 2012 Mar 22;12(4):269-81.

35.

Gill S, June CH. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. *Immunological Reviews*. 2015 Jan;263(1):68–89.

36.

Barrett DM, Grupp SA, June CH. Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street. *The Journal of Immunology*. 2015 Aug 1;195(3):755–61.

37.

Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. *Nature Reviews Cancer*. 2012 Mar 22;12(4):265–77.